Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Trading 4.7% Higher – Should You Buy?

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) was up 4.7% on Tuesday . The company traded as high as $1.82 and last traded at $1.80. Approximately 1,331,886 shares traded hands during trading, an increase of 8% from the average daily volume of 1,228,101 shares. The stock had previously closed at $1.72.

Analyst Ratings Changes

Several equities analysts have issued reports on LCTX shares. HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of Lineage Cell Therapeutics in a research note on Monday, November 24th. D. Boral Capital restated a “buy” rating and issued a $2.00 price target on shares of Lineage Cell Therapeutics in a report on Tuesday, November 25th. Four equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $4.25.

Lineage Cell Therapeutics Stock Performance

The business has a 50-day moving average of $1.74 and a 200-day moving average of $1.35. The stock has a market capitalization of $414.59 million, a price-to-earnings ratio of -6.21 and a beta of 1.78.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.11). The firm had revenue of $3.68 million for the quarter, compared to analyst estimates of $2.30 million. Lineage Cell Therapeutics had a negative return on equity of 72.02% and a negative net margin of 625.53%. On average, research analysts predict that Lineage Cell Therapeutics, Inc. will post -0.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Citizens Financial Group Inc. RI acquired a new stake in shares of Lineage Cell Therapeutics during the third quarter worth about $25,000. Kapitalo Investimentos Ltda purchased a new stake in Lineage Cell Therapeutics during the 2nd quarter valued at approximately $25,000. Jump Financial LLC acquired a new stake in Lineage Cell Therapeutics during the 2nd quarter worth approximately $28,000. Cannon Global Investment Management LLC acquired a new stake in Lineage Cell Therapeutics during the 2nd quarter worth approximately $30,000. Finally, Integrity Alliance LLC. grew its stake in shares of Lineage Cell Therapeutics by 75.0% in the 2nd quarter. Integrity Alliance LLC. now owns 35,000 shares of the company’s stock valued at $32,000 after purchasing an additional 15,000 shares during the last quarter. 62.47% of the stock is currently owned by institutional investors and hedge funds.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.